Clinical Trials Logo

Idiopathic Parkinson Disease clinical trials

View clinical trials related to Idiopathic Parkinson Disease.

Filter by:

NCT ID: NCT01227265 Completed - Parkinson Disease Clinical Trials

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Start date: November 19, 2010
Phase: Phase 3
Study type: Interventional

This is a study of the efficacy and safety of preladenant in adult participants with moderate to severe Parkinson's Disease (PD). While on this study, participants will continue to take their usual, prescribed, stable regimen of levodopa (L-dopa) or L-dopa plus adjunct PD medications and will be randomized to receive 2 mg preladenant, 5 mg preladenant, or placebo, twice daily, for 12 weeks. After that, participants may choose to receive additional treatment with preladenant. The primary hypothesis is that at least the 5 mg twice daily dose of preladenant is superior to placebo as measured by the change from Baseline to Week 12 in the mean "off" time.

NCT ID: NCT01215227 Terminated - Parkinson Disease Clinical Trials

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

Start date: November 18, 2010
Phase: Phase 3
Study type: Interventional

The primary purpose of this extension study is to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and NCT01227265 [P07037] with moderate to severe Parkinson's Disease (PD). The study will also characterize the long-term efficacy of preladenant in participants with PD. Participants will continue to receive their stable regimen of levodopa (L-dopa) plus any adjunct medications during the study as prescribed by their physician. Several classes of adjunct medications may be used, including Amantadine, anticholinergics, dopa decarboxylase inhibitors, and dopamine agonists.

NCT ID: NCT00599339 Completed - Clinical trials for Idiopathic Parkinson Disease

Transdermal Rotigotine User Surveillance Study

TRUST
Start date: June 2006
Phase:
Study type: Observational

This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.

NCT ID: NCT00437125 Completed - Clinical trials for Major Depressive Disorder

Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease

Start date: March 2007
Phase: Phase 4
Study type: Interventional

This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.

NCT ID: NCT00160576 Completed - Clinical trials for Idiopathic Parkinson Disease

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Start date: July 2003
Phase: Phase 2
Study type: Interventional

This is a 41-week trial composed of two consecutive parts (Part A, 14 weeks and optional Part B, 27 weeks) to evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with Idiopathic Parkinson's Disease, without negative impact on the benefit on the motor function of the antiparkinsonian treatment.